Condition: BRAF V600 Mutation · Low-grade Glioma · Low Grade Glioma of Brain · Sponsor: University of California, San Francisco
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals tumor cells to multiply. This helps stop the spread of tumor cells. This trial may help doctors determine the best dosing strategy for patients who have received dabrafenib and trametinib for 12-24 months: Either stopping dabrafenib and trametinib completely or slowly reducing the dose for an additional 6 months.
This description comes directly from the study's public registry record.
Jacqueline Ayyoub · 415-502-1600 · PNOC037@ucsf.edu
Kelly Hitchner · 415-502-1600 · PNOC037@ucsf.edu
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| John Hopkins Medical Center | Baltimore, Maryland, United States | Recruiting |
| St. Louis Children's Hospital Washington University in St. Louis | St Louis, Missouri, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
| St. Jude Children's Research Hospital | Memphis, Tennessee, United States | Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07110246